Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the above-identified application:

1-30. **(Canceled)**

31. **(Withdrawn)** A method for crystallizing Hepatitis C virus helicase comprising growing a crystal from a precipitant solution comprising purified Hepatitis C virus helicase, about 3% by weight to about 14% by weight PEG, about 5% by weight to about 15% by weight DMSO, and about 0.05M to about 0.07M potassium phosphate, wherein the amino acid sequence of Hepatitis C virus helicase is SEQ ID NO:1.

32-34. **(Canceled)**

35. **(Withdrawn)** A method for crystallizing Hepatitis C virus helicase comprising growing a crystal by vapor diffusion with macro-seeding from a precipitant solution comprising purified Hepatitis C virus helicase, HEPES, and about 4% by weight to about 14% by weight mono-alkyl ether of PEG, wherein the amino acid sequence of the Hepatitis C virus helicase is SEQ ID NO:1.

36-37. **(Canceled)**

38. **(Previously Presented)** Crystalline Hepatitis C virus helicase comprising a tetragonal crystal having unit cell dimensions of a = b = 109 Å ± 3 Å; c = 84 Å ± 2 Å; $\alpha = \beta = \gamma = 90°$; and space group $P4_1$; the unit cell containing two molecules in an asymmetric unit.

39. **(Previously Presented)** The crystalline Hepatitis C virus helicase of claim 38 wherein the amino acid sequence of the Hepatitis C virus helicase is SEQ ID NO:1.

40. **(Previously Presented)** Crystalline Hepatitis C virus helicase comprising an orthorhombic crystal characterized by unit cell dimensions of a = 66 Å ± 2 Å; b = 110 Å ± 3 Å; c = 64 Å ± 2 Å; $\alpha = \beta = \gamma = 90°$; and a space group $P2_12_12$; the unit cell containing one molecule in the asymmetric unit.

41. **(Previously Presented)** The crystalline Hepatitis C virus helicase of claim 40 wherein the amino acid sequence of the Hepatitis C virus helicase is SEQ ID NO:1.

42. **(Currently Amended)** The ~~C~~crystalline Hepatitis C virus helicase ~~having~~ of claim 38 wherein the Hepatitis C virus helicase is amino acid sequence SEQ ID NO:1[[,]] and wherein the crystalline Hepatitis C virus helicase effectively diffracts x-rays to a resolution of 1.5 Å to 3 Å.

43. **(Previously Presented)** A composition comprising crystalline Hepatitis C virus helicase of any of claims 38-41.

44-46. **(Canceled)**

47. (**Withdrawn**) A method for incorporating a chemical entity in a crystal comprising placing a tetragonal crystal of Hepatitis C virus helicase having unit cell dimensions of a = b = 109 Å ± 3 Å; c = 84 Å ± 2 Å; $\alpha = \beta = \gamma = 90°$; the unit cell containing two molecules in an asymmetric unit; and space group $P4_1$ in an aqueous solution comprising about 1mM to about 10mM chemical entity, and 0% by weight to about 15% by weight DMSO.

48. (**Withdrawn**) A method for incorporating a chemical entity in a crystal comprising placing an orthorhombic crystal of Hepatitis C virus helicase having unit cell dimensions of a = 66 Å ± 2 Å; b = 110 Å ± 3 Å; c = 64 Å ± 2 Å; $\alpha = \beta = \gamma = 90°$; the unit cell containing one molecule in the asymmetric unit; and a space group $P2_12_12$ in an aqueous solution comprising about 1mM to about 10mM chemical entity, and 0% by weight to about 15% by weight DMSO.

49-50. (**Canceled**)

51. (**Currently Amended**) ~~A crystal of~~ The crystalline Hepatitis C virus helicase [[,]] of claim 38 wherein the Hepatitis C virus helicase ~~comprises~~ is amino acid sequence SEQ ID NO:1, with the proviso that at least one cysteine or methionine is replaced with selenocysteine or selenomethionine, respectively~~, and wherein the crystal effectively diffracts x-rays to a resolution of 1.5 Å to 3 Å~~.

52-54. (**Canceled**)

55. (**Currently Amended**) ~~A crystal of~~ The crystalline Hepatitis C virus helicase ~~comprising~~ of claim 38 wherein the Hepatitis C virus helicase crystal comprises atoms arranged in a spatial relationship represented by the structure coordinates listed in Table 1.

56. (**Currently Amended**) ~~A crystal of~~ The crystalline Hepatitis C virus helicase ~~comprising~~ of claim 38 wherein the Hepatitis C virus helicase crystal comprises atoms arranged in a spatial relationship represented by the structure coordinates listed in Table 2.

57. (**Currently Amended**) ~~A crystal of~~ The crystalline Hepatitis C virus helicase ~~comprising~~ of claim 40 wherein the Hepatitis C virus helicase crystal comprises atoms arranged in a spatial relationship represented by the structure coordinates listed in Table 3.

58. (**Currently Amended**) ~~A crystal of~~ The crystalline Hepatitis C virus helicase of claim 38 wherein the Hepatitis C virus helicase crystal is prepared by a method comprising growing a crystal from a precipitant solution comprising purified Hepatitis C virus helicase, about 3% by weight to about 14% by weight PEG, about 5% by weight to about 15% by weight DMSO, and about 0.05M to about 0.07M potassium phosphate, wherein the amino acid sequence of the Hepatitis C virus helicase is SEQ ID NO:1.

59. (**Currently Amended**) ~~A crystal of~~ The crystalline Hepatitis C virus helicase of claim 40 wherein the Hepatitis C virus helicase is prepared by a method comprising growing a crystal by vapor

diffusion with macro-seeding from a precipitant solution comprising purified Hepatitis C virus helicase, HEPES, and about 4% by weight to about 14% by weight mono-alkyl ether of PEG, wherein the amino acid sequence of the Hepatitis C virus helicase is SEQ ID NO:1.

60-61. **(Canceled)**

62. **(New)** The crystalline Hepatitis C virus helicase of claim 40 wherein Hepatitis C virus helicase is amino acid sequence SEQ ID NO:1 and wherein the crystalline Hepatitis C virus helicase effectively diffracts x-rays to a resolution of 1.5 Å to 3 Å.

63. **(New)** The crystalline Hepatitis C virus helicase of claim 40 wherein the Hepatitis C virus helicase crystal is amino acid sequence SEQ ID NO:1, with the proviso that at least one cysteine or methionine is replaced with selenocysteine or selenomethionine, respectively.